{"id":8688,"date":"2022-06-07T12:30:08","date_gmt":"2022-06-07T16:30:08","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/pharmaceuticals-and-deceptive-advertising-when-can-you-sue\/"},"modified":"2022-06-07T12:30:08","modified_gmt":"2022-06-07T16:30:08","slug":"ilac-ve-aldatici-reklam-ne-zaman-dava-yapabilirsin","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/article\/ilac-ve-aldatici-reklam-ne-zaman-dava-yapabilirsin\/","title":{"rendered":"\u0130la\u00e7 ve Aldat\u0131c\u0131 Reklam: Ne Zaman Dava A\u00e7abilirsiniz?"},"content":{"rendered":"<h1><span style=\"font-weight: 400;\">\u0130la\u00e7 ve Aldat\u0131c\u0131 Reklam: Ne Zaman Dava A\u00e7abilirsiniz?<\/span><\/h1>\n<p><span style=\"font-weight: 400;\">\u0130la\u00e7, Amerika Birle\u015fik Devletleri&#039;nde milyarlarca dolarl\u0131k bir end\u00fcstridir. Ancak, bu t\u00fcr bir para s\u00f6z konusu oldu\u011funda, aldat\u0131c\u0131 reklamc\u0131l\u0131k uygulamalar\u0131na giri\u015ferek k\u00f6\u015feleri kestirmeye \u00e7al\u0131\u015fan \u015firketler var.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">nedeniyle zarar g\u00f6rd\u00fcyseniz veya yaraland\u0131ysan\u0131z <\/span><a href=\"\/tr\/uygulama-alanlari-2\/ilac-davasi\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ila\u00e7lar<\/span><\/a><span style=\"font-weight: 400;\"> aldat\u0131c\u0131 pazarlama sonucunda \u00fcreticiyi dava edebilirsiniz. Aldat\u0131c\u0131 reklamlar\u0131n dava nedeni oldu\u011fu ABD&#039;deki farmas\u00f6tik reklam yasas\u0131n\u0131n temellerini ve baz\u0131 \u00f6rnek vakalar\u0131 \u00f6\u011frenmek i\u00e7in okumaya devam edin.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">FDA ve FTC&#039;nin Farmas\u00f6tik Reklam Yasalar\u0131na ve Kurallar\u0131na \u0130li\u015fkin Temel Bilgiler<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Amerika Birle\u015fik Devletleri G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), Amerika Birle\u015fik Devletleri&#039;nde sat\u0131lan t\u00fcm ila\u00e7lar\u0131n g\u00fcvenli ve etkili olmas\u0131n\u0131 sa\u011flamaktan sorumludur. bu <\/span><a href=\"\/tr\/article\/fda-onayli-gercekten-ne-anlama-geliyor\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA ayr\u0131ca reklamlar\u0131 da d\u00fczenler<\/span><\/a><span style=\"font-weight: 400;\"> ve ila\u00e7lar\u0131n tan\u0131t\u0131m\u0131.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Federal Ticaret Komisyonu (FTC), yan\u0131lt\u0131c\u0131 ve haks\u0131z i\u015f uygulamalar\u0131n\u0131 \u00f6nlemekten sorumludur. FTC&#039;nin, ila\u00e7 end\u00fcstrisi de dahil olmak \u00fczere t\u00fcm end\u00fcstriler i\u00e7in ge\u00e7erli olan ve FTC Yasas\u0131 olarak bilinen bir dizi kural\u0131 vard\u0131r.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u0130la\u00e7 end\u00fcstrisi s\u00f6z konusu oldu\u011funda, FDA daha reaktif ve FTC daha proaktiftir. FDA re\u00e7eteli ila\u00e7 d\u00fczenlemelerini denetlerken, Federal Ticaret Komisyonu re\u00e7etesiz sat\u0131lan ila\u00e7lardan sorumludur.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Aldat\u0131c\u0131 Reklam Ne Zaman Dava Sebebidir?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Aldat\u0131c\u0131 reklam, bir \u015firketin \u00fcr\u00fcnleri hakk\u0131nda yanl\u0131\u015f veya yan\u0131lt\u0131c\u0131 iddialarda bulunmas\u0131d\u0131r. Farmas\u00f6tik pazarlama, g\u00f6r\u00fcnd\u00fckleri medyadan ba\u011f\u0131ms\u0131z olarak, reklam\u0131n ana b\u00f6l\u00fcm\u00fcnde belirli temel bile\u015fenleri i\u00e7ermelidir:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0130lac\u0131n ad\u0131 (marka ve jenerik)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0130la\u00e7 i\u00e7in en az bir FDA onayl\u0131 kullan\u0131m<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0130lac\u0131n en \u00f6nemli riskleri<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Re\u00e7eteli bir ilac\u0131n yararlar\u0131 ve riskleri dengeli bir \u015fekilde<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0130lac\u0131n k\u0131sa \u00f6zeti<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Bir farmas\u00f6tik reklam\u0131 bu temel bile\u015fenleri i\u00e7ermiyorsa, yanl\u0131\u015f veya yan\u0131lt\u0131c\u0131 olarak kabul edilir ve yan\u0131lt\u0131c\u0131 reklam i\u00e7in bir davan\u0131z olabilir. M\u00fc\u015fteriler ve izleyiciler, aldat\u0131c\u0131 ila\u00e7 reklamlar\u0131n\u0131 FDA veya FTC&#039;ye bildirmeye te\u015fvik edilir.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ancak, fark\u0131nda olun <\/span><i><span style=\"font-weight: 400;\">sadece<\/span><\/i><span style=\"font-weight: 400;\"> bir reklam\u0131n aldat\u0131c\u0131 olarak de\u011ferlendirilebilmesi, \u00fcreticiye kar\u015f\u0131 bir davan\u0131z oldu\u011fu anlam\u0131na gelmez. Ayr\u0131ca, ilac\u0131n \u00f6nemli \u00f6l\u00e7\u00fcde zarar verme potansiyeline sahip oldu\u011funu veya reklam\u0131n ba\u015far\u0131l\u0131 olmas\u0131 nedeniyle zaten size zarar vermi\u015f oldu\u011funu kan\u0131tlaman\u0131z gerekir. Zarara y\u00f6nelik bir durum yokken \u015firketleri \u201cyakalamaya\u201d y\u00f6nelik anlams\u0131z davalar ba\u015far\u0131l\u0131 olamayacak.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">\u0130la\u00e7 ve Aldat\u0131c\u0131 Reklamlara \u0130li\u015fkin \u00d6rnek Vakalar<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">\u0130nsanlar\u0131n aldat\u0131c\u0131 reklamlar nedeniyle ila\u00e7 \u015firketlerine dava a\u00e7t\u0131\u011f\u0131 pek \u00e7ok farmas\u00f6tik vaka \u00f6rne\u011fi vard\u0131r. Bir\u00e7ok t\u00fcketim mallar\u0131 davas\u0131 olsa da, a\u015fa\u011f\u0131daki ila\u00e7 davalar\u0131 ger\u00e7ekten zarar vermi\u015f veya en az\u0131ndan ciddi zarar verme potansiyeline sahip g\u00f6ze \u00e7arpan davalard\u0131r.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">2013 y\u0131l\u0131nda, <\/span><a href=\"https:\/\/www.justice.gov\/opa\/pr\/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FTC bir davay\u0131 \u00e7\u00f6zd\u00fc<\/span><\/a><span style=\"font-weight: 400;\"> Johnson &amp; Johnson ile $2.205 milyar. Dava, \u015firketin FDA taraf\u0131ndan onaylanmayan kullan\u0131mlar i\u00e7in re\u00e7eteli ila\u00e7lar Risperdal, Invega, Natrecor&#039;un yasad\u0131\u015f\u0131 tan\u0131t\u0131m\u0131n\u0131 i\u00e7eriyordu.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">2019&#039;daki daha yeni bir vakada, bir vaka <\/span><a href=\"https:\/\/www.drugwatch.com\/xarelto\/lawsuits\/#:~:text=Xarelto%20users%20sued%20Johnson%20%26%20Johnson,%24775%20million%20in%20March%202019.\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">$775 milyona yerle\u015fti<\/span><\/a><span style=\"font-weight: 400;\"> Bayer Corporation&#039;\u0131n yan\u0131 s\u0131ra Johnson &amp; Johnson ve Janssen Pharmaceuticals&#039;a kar\u015f\u0131. Bu \u015firketler, Xarelto ilac\u0131yla ilgili riskleri k\u00fc\u00e7\u00fcmsemek ve aldat\u0131c\u0131 bir \u015fekilde Xarelto ilac\u0131n\u0131n reklam\u0131n\u0131 yapmakla su\u00e7luydu.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Devam eden <\/span><a href=\"\/tr\/devlet-isleri-opioid-avukat-dairesi\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">opioid krizi<\/span><\/a><span style=\"font-weight: 400;\"> yan\u0131lt\u0131c\u0131 pazarlaman\u0131n, opioidlerin nas\u0131l ele al\u0131nd\u0131\u011f\u0131 ve re\u00e7ete edildi\u011fine ili\u015fkin \u015fikayetlerden yaln\u0131zca biri oldu\u011fu g\u00fcn\u00fcm\u00fczde, zararl\u0131 ila\u00e7 pazarlamas\u0131n\u0131n en yayg\u0131n ve derin \u00f6rneklerinden biridir. Opioidler ba\u015flang\u0131\u00e7ta doktorlara ve eczac\u0131lara ve ard\u0131ndan halka ba\u011f\u0131ml\u0131l\u0131k yapmayan, zarars\u0131z ila\u00e7lar olarak sunuldu ve bu da onlar\u0131n yayg\u0131n bir \u015fekilde re\u00e7etelenmesine ve kullan\u0131lmas\u0131na yol a\u00e7t\u0131 - \u00e7\u0131lg\u0131nca, tehlikeli bir \u015fekilde yanl\u0131\u015f oldu\u011fu kan\u0131tlanm\u0131\u015f bir iddia.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Opioid davalar\u0131 art\u0131k doktorlara, hastanelere ve ila\u00e7 \u015firketlerine milyarlarca dolara mal oluyor. Napoli Shkolnik&#039;in opioid avukatlar\u0131 yak\u0131n zamanda ula\u015ft\u0131 <\/span><a href=\"\/tr\/article\/partner-kavgalari-opioid-salgin-kazandi-2-5m-hukum\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">son bir yerle\u015fim<\/span><\/a><span style=\"font-weight: 400;\"> $ i\u00e7in 2,5 milyon trajik bir \u015fekilde benzer bir\u00e7ok vakadan sadece birinde opioidler ve benzodiazepinlerin \u00f6l\u00fcmc\u00fcl bir kombinasyonu re\u00e7ete edilen bir adam\u0131n ailesi i\u00e7in. Avukatlar\u0131m\u0131z \u015fu anda opioid \u00fcreticilerine kar\u015f\u0131 New York ve Ohio&#039;daki en \u00f6nemli davalar\u0131 da y\u00fcr\u00fct\u00fcyor.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bu vakalar, yaln\u0131zca yan\u0131lt\u0131c\u0131 pazarlamadan \u00e7ok daha fazla yasa d\u0131\u015f\u0131 ve tehlikeli uygulamay\u0131 i\u00e7erse de, opioid ila\u00e7lar\u0131n pervas\u0131zca re\u00e7etelenmesine yol a\u00e7an yanl\u0131\u015f bilgilendirmenin katk\u0131da bulunan nedenlerinden biri oldu\u011fu inkar edilemez.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Aldat\u0131c\u0131 Reklamlar Sonucu \u0130la\u00e7lar Taraf\u0131ndan Yaraland\u0131n\u0131z m\u0131?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Aldat\u0131c\u0131 reklamlar sonucunda siz veya yak\u0131n\u0131n\u0131z ila\u00e7lardan yaraland\u0131ysa, as\u0131ls\u0131z iddialar\u0131 nedeniyle \u00fcreticiye kar\u015f\u0131 dava a\u00e7abilirsiniz. deneyimli ila\u00e7 avukatlar\u0131 <\/span><a href=\"\/tr\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Napoli Shkolnik<\/span><\/a><span style=\"font-weight: 400;\"> talebinizi ara\u015ft\u0131rman\u0131za ve hak etti\u011finiz tazminat i\u00e7in m\u00fccadele etmenize yard\u0131mc\u0131 olabilir. <\/span><a href=\"\/tr\/bize-ulasin\/\"><span style=\"font-weight: 400;\">Bize Ula\u015f\u0131n<\/span><\/a><span style=\"font-weight: 400;\"> bug\u00fcn davan\u0131z\u0131 g\u00f6r\u00fc\u015fmek \u00fczere.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>\u0130la\u00e7 ve Aldat\u0131c\u0131 Reklam: Ne Zaman Dava A\u00e7abilirsiniz? \u0130la\u00e7, Amerika Birle\u015fik Devletleri&#039;nde milyarlarca dolarl\u0131k bir end\u00fcstridir. Ancak, bu t\u00fcr bir para s\u00f6z konusu oldu\u011funda, \u015fu \u015firketler var ki\u2026<\/p>","protected":false},"author":3,"featured_media":8689,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[776],"tags":[816,820,914,917,918,926,928,942,972,978,1082],"class_list":["post-8688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-litigation","tag-defective-products","tag-product-liability","tag-pharmaceutical-litigation-attorney","tag-pharmaceutical-lawsuit","tag-pharmaceutical-lawyers","tag-pharmaceutical-law","tag-pharmaceutical-lawsuit-attorney","tag-opioid-crisis","tag-fda-recall","tag-fda-warning","tag-deceptive-marketing"],"acf":[],"page_builder_type":"gutenberg","gutenberg_data":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts\/8688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/comments?post=8688"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts\/8688\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media\/8689"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=8688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/categories?post=8688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/tags?post=8688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}